Last reviewed · How we verify
The usual treatment
At a glance
| Generic name | The usual treatment |
|---|---|
| Sponsor | Mohammad Sadegh Bagheri Baghdasht |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" (NA)
- Shared Decision-Making Decision Aid for Newly Diagnosed Breast Cancer : A Multi-Center Randomized Controlled Trial (NA)
- The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares (NA)
- Reducing Symptom Burden Through Physical Exercise in Melanoma Patients (NA)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The usual treatment CI brief — competitive landscape report
- The usual treatment updates RSS · CI watch RSS
- Mohammad Sadegh Bagheri Baghdasht portfolio CI